Résumé
It is well established that an elevated potassium level (hyperkalemia) is associated with a risk of adverse events including morbidity, mortality and healthcare system cost. Hyperkalemia is commonly encountered in many chronic conditions including kidney disease, diabetes and heart failure. Furthermore, hyperkalemia may result from the use of renin-angiotensin-aldosterone system inhibitors (RAASi), which are disease-modifying treatments for these conditions. Therefore, balancing the benefits of optimizing treatment with RAASi while mitigating hyperkalemia is crucial to ensure patients are optimally treated. In this review, we will briefly discuss the definition, causes, epidemiology and consequences of hyperkalemia. The majority of the review will be focused on management of hyperkalemia in the acute and chronic setting, emphasizing contemporary approaches and evolving data on the relevance of dietary restriction and the use of novel potassium binders.
| Langue d'origine | English |
|---|---|
| Journal | Cardiology and Therapy |
| DOI | |
| Statut de publication | Accepted/In press - 2022 |
Note bibliographique
Funding Information:Jacob B. Michaud, Natasha L. Larivée, Keigan M. More and Jo-Anne Wilson have nothing to disclose. Karthik K. Tennankore has done consultancy, advisory board and CME work for Otsuka, AstraZeneca, GSK, Bayer and Vifor and CME. He has received unrestricted investigator initiated grant funding from Otsuka for an unrelated project.
Publisher Copyright:
© 2022, The Author(s).
ASJC Scopus Subject Areas
- Cardiology and Cardiovascular Medicine
PubMed: MeSH publication types
- Journal Article
- Review
ODD de l’ONU
Cette action contribue à la réalisation des objectifs de développement durable suivants
